The role of botulinum toxin type A related axon transport in neuropathic pain induced by chronic constriction injury
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The mechanism of peripheral axon transport in neuropathic pain is still unclear. Chemokine ligand 13 (CXCL13) and its receptor (C-X-C chemokine receptor type 5, CXCR5) as well as GABA transporter 1 (GAT-1) play an important role in the development of pain. The aim of this study was to explore the axonal transport of CXCL13/CXCR5 and GAT-1 with the aid of the analgesic effect of botulinum toxin type A (BTX-A) in rats. Methods: Chronic constriction injury (CCI) rat models were established. BTX-A was administered to rats through subcutaneous injection in the hind paw. The pain behaviors in CCI rats were measured by paw withdrawal threshold and paw withdrawal latencies. The levels of CXCL13/CXCR5 and GAT-1 were measured by western blots. Results: The subcutaneous injection of BTX-A relieved the mechanical allodynia and heat hyperalgesia induced by CCI surgery and reversed the overexpression of CXCL13/CXCR5 and GAT-1 in the spinal cord, dorsal root ganglia (DRG), sciatic nerve, and plantar skin in CCI rats. After 10 mmol/L colchicine blocked the axon transport of sciatic nerve, the inhibitory effect of BTX-A disappeared, and the levels of CXCL13/CXCR5 and GAT-1 in the spinal cord and DRG were reduced in CCI rats. Conclusions: BTX-A regulated the levels of CXCL13/CXCR5 and GAT-1 in the spine and DRG through axonal transport. Chemokines (such as CXCL13) may be transported from the injury site to the spine or DRG through axonal transport. Axon molecular transport may be a target to enhance pain management in neuropathic pain.
Abstract
Background: The mechanism of peripheral axon transport in neuropathic pain is still unclear. Chemokine ligand 13 (CXCL13) and its receptor (C-X-C chemokine receptor type 5, CXCR5) as well as GABA transporter 1 (GAT-1) play an important role in the development of pain. The aim of this study was to explore the axonal transport of CXCL13/CXCR5 and GAT-1 with the aid of the analgesic effect of botulinum toxin type A (BTX-A) in rats. Methods: Chronic constriction injury (CCI) rat models were established. BTX-A was administered to rats through subcutaneous injection in the hind paw. The pain behaviors in CCI rats were measured by paw withdrawal threshold and paw withdrawal latencies. The levels of CXCL13/CXCR5 and GAT-1 were measured by western blots. Results: The subcutaneous injection of BTX-A relieved the mechanical allodynia and heat hyperalgesia induced by CCI surgery and reversed the overexpression of CXCL13/CXCR5 and GAT-1 in the spinal cord, dorsal root ganglia (DRG), sciatic nerve, and plantar skin in CCI rats. After 10 mmol/L colchicine blocked the axon transport of sciatic nerve, the inhibitory effect of BTX-A disappeared, and the levels of CXCL13/CXCR5 and GAT-1 in the spinal cord and DRG were reduced in CCI rats. Conclusions: BTX-A regulated the levels of CXCL13/CXCR5 and GAT-1 in the spine and DRG through axonal transport. Chemokines (such as CXCL13) may be transported from the injury site to the spine or DRG through axonal transport. Axon molecular transport may be a target to enhance pain management in neuropathic pain.
참고문헌 (25)
- Baba M, "Mirogabalin in Japanese patients with renal impairment and pain associated with diabetic peripheral neuropathy or post-herpetic neuralgia : a phase III, open-label, 14-week study", J Pain Res, 13, pp.1811~1821 (2020)
- Rodríguez MJ, "Costeffectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia", Curr Med Res Opin, 23, pp.2585~2596 (2007)
- Gerken JD, "Retrospective study on ganglionic and nerve block series as therapeutic option for chronic pain patients with refractory neuropathic pain", Pain Res Manag, 2020, pp.6042941~ (2020)
- Liu B, "Clinical study of spinal cord stimulation and pulsed radiofrequency for management of herpes zoster-related pain persisting beyond acute phase in elderly patients", Pain Physician, 23, pp.263~270 (2020)
- Li Z, "HDAC2, but not HDAC1, regulates Kv1.2 expression to mediate neuropathic pain in CCI rats", Neuroscience, 408, pp.339~348 (2019)
- Tal M, "Abnormal discharge originates at the site of nerve injury in experimental constriction neuropathy(CCI)in the rat", Pain, 64, pp.511~518 (1996)
- Zhang JM, "Decreasing sympathetic sprouting in pathologic sensory ganglia : a new mechanism for treating neuropathic pain using lidocaine", Pain, 109, pp.143~149 (2004)
- Serra J, "Microneurographic identification of spontaneous activity in Cnociceptors in neuropathic pain states in humans and rats", Pain, 153, pp.42~55 (2012)
- Li L, "MiR-30b-5p attenuates oxaliplatin-induced peripheral neuropathic pain through the voltage-gated sodium channel Nav1.6 in rats", Neuropharmacology, 153, pp.111~120 (2019)
- Matak I, "Botulinum toxin’s axonal transport from periphery to the spinal cord", Neurochem Int, 61, pp.236~239 (2012)
- Bu HL, "The roles of chemokine CXCL13 in the development of bone cancer pain and the regulation of morphine analgesia in rats", Neuroscience, 406, pp.62~72 (2019)
- Ford A, "Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain", J Neurosci, 35, pp.6057~6067 (2015)
- Bennett GJ, "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man", Pain, 33, pp.87~107 (1988)
- Dilley A, "Disruption of axoplasmic transport induces mechanical sensitivity in intact rat C-fibre nociceptor axons", J Physiol, 586, pp.593~604 (2008)
- Akaike N, "Transsynaptic inhibition of spinal transmission by A2 botulinum toxin", J Physiol, 591, pp.1031~1043 (2013)
- Zychowska M, "Participation of pro-and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain", Eur J Pharmacol, 791, pp.377~388 (2016)
- Curtis R, "Neuronal injury increases retrograde axonal transport of the neurotrophins to spinal sensory neurons and motor neurons via multiple receptor mechanisms", Mol Cell Neurosci, 12, pp.105~118 (1998)
- Myers RR, "The ology of neuropathy : an integrative review of the role of neuroinflammation and TNF-α axonal transport in neuropathic pain", J Peripher Nerv Syst, 16, pp.277~286 (2011)
- Sung YJ, "Activation and retrograde transport of protein kinase G in rat nociceptive neurons after nerve injury and inflammation", Neuroscience, 141, pp.697~709 (2006)
- Reaux-Le Goazigo A, "Cellular and subcellular localization of CXCL12 and CXCR4 in rat nociceptive structures : physiological relevance", Eur J Neurosci, 36, pp.2619~2631 (2012)
- Laganà M, "The G proteincoupled receptor kinases(GRKs)in chemokine receptormediated immune cell migration : from molecular cues to physiopathology", Cells, 10, pp.75~ (2021)
- Schioppa T, "Molecular basis for CCRL2 regulation of leukocyte migration", Front Cell Dev Biol, 8, pp.615031~ (2020)
- Jiang BC, "Chemokines in chronic pain : cellular and molecular mechanisms and therapeutic potential", Pharmacol Ther, 212, pp.107581~ (2020)
- Lau S, "A negative-feedback loop maintains optimal chemokine concentrations for directional cell migration", Nat Cell Biol, 22, pp.266~273 (2020)
- Proske U, "Mechanical sensitivity of muscle afferents in a nerve treated with colchicine", Exp Brain Res, 119, pp.391~398 (1998)